|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: AMBP |
Gene summary for AMBP |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | AMBP | Gene ID | 259 |
| Gene name | alpha-1-microglobulin/bikunin precursor | |
| Gene Alias | A1M | |
| Cytomap | 9q32 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | P02760 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 259 | AMBP | NAFLD1 | Human | Liver | NAFLD | 5.03e-04 | -4.31e-01 | -0.04 |
| 259 | AMBP | S43 | Human | Liver | Cirrhotic | 1.42e-21 | -3.41e-01 | -0.0187 |
| 259 | AMBP | HCC1_Meng | Human | Liver | HCC | 1.40e-15 | 4.01e-01 | 0.0246 |
| 259 | AMBP | HCC2_Meng | Human | Liver | HCC | 1.16e-68 | -1.44e+00 | 0.0107 |
| 259 | AMBP | cirrhotic1 | Human | Liver | Cirrhotic | 6.98e-06 | 3.83e-01 | 0.0202 |
| 259 | AMBP | cirrhotic2 | Human | Liver | Cirrhotic | 1.02e-04 | 3.41e-01 | 0.0201 |
| 259 | AMBP | HCC1 | Human | Liver | HCC | 8.17e-27 | 6.71e+00 | 0.5336 |
| 259 | AMBP | HCC2 | Human | Liver | HCC | 1.56e-31 | 7.53e+00 | 0.5341 |
| 259 | AMBP | HCC5 | Human | Liver | HCC | 5.04e-08 | 4.52e+00 | 0.4932 |
| 259 | AMBP | Pt13.a | Human | Liver | HCC | 7.52e-19 | 3.64e-01 | 0.021 |
| 259 | AMBP | Pt13.b | Human | Liver | HCC | 2.64e-31 | 1.47e-01 | 0.0251 |
| 259 | AMBP | Pt13.c | Human | Liver | HCC | 1.46e-08 | 4.87e-01 | 0.0076 |
| 259 | AMBP | Pt14.b | Human | Liver | HCC | 2.66e-05 | 2.77e-01 | 0.018 |
| 259 | AMBP | S014 | Human | Liver | HCC | 3.21e-27 | 3.61e+00 | 0.2254 |
| 259 | AMBP | S015 | Human | Liver | HCC | 1.62e-32 | 4.43e+00 | 0.2375 |
| 259 | AMBP | S016 | Human | Liver | HCC | 4.40e-23 | 3.79e+00 | 0.2243 |
| 259 | AMBP | S027 | Human | Liver | HCC | 8.75e-29 | 4.30e+00 | 0.2446 |
| 259 | AMBP | S028 | Human | Liver | HCC | 8.67e-39 | 4.26e+00 | 0.2503 |
| 259 | AMBP | S029 | Human | Liver | HCC | 5.67e-41 | 5.19e+00 | 0.2581 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000091015 | Esophagus | HGIN | cytokinesis | 44/2587 | 173/18723 | 3.26e-05 | 8.32e-04 | 44 |
| GO:00616406 | Esophagus | HGIN | cytoskeleton-dependent cytokinesis | 27/2587 | 100/18723 | 3.71e-04 | 5.77e-03 | 27 |
| GO:00002816 | Esophagus | HGIN | mitotic cytokinesis | 19/2587 | 71/18723 | 2.90e-03 | 2.81e-02 | 19 |
| GO:00706463 | Esophagus | HGIN | protein modification by small protein removal | 34/2587 | 157/18723 | 4.68e-03 | 4.02e-02 | 34 |
| GO:000028115 | Esophagus | ESCC | mitotic cytokinesis | 58/8552 | 71/18723 | 4.34e-10 | 1.15e-08 | 58 |
| GO:000091016 | Esophagus | ESCC | cytokinesis | 115/8552 | 173/18723 | 2.48e-08 | 4.68e-07 | 115 |
| GO:006164015 | Esophagus | ESCC | cytoskeleton-dependent cytokinesis | 72/8552 | 100/18723 | 8.10e-08 | 1.39e-06 | 72 |
| GO:000726510 | Esophagus | ESCC | Ras protein signal transduction | 201/8552 | 337/18723 | 1.44e-07 | 2.30e-06 | 201 |
| GO:007064612 | Esophagus | ESCC | protein modification by small protein removal | 95/8552 | 157/18723 | 1.25e-04 | 8.56e-04 | 95 |
| GO:00465789 | Esophagus | ESCC | regulation of Ras protein signal transduction | 106/8552 | 189/18723 | 2.49e-03 | 1.08e-02 | 106 |
| GO:00165793 | Esophagus | ESCC | protein deubiquitination | 79/8552 | 139/18723 | 5.23e-03 | 1.97e-02 | 79 |
| GO:005105610 | Esophagus | ESCC | regulation of small GTPase mediated signal transduction | 157/8552 | 302/18723 | 1.55e-02 | 4.98e-02 | 157 |
| GO:00194396 | Liver | NAFLD | aromatic compound catabolic process | 102/1882 | 467/18723 | 2.29e-14 | 1.91e-11 | 102 |
| GO:19013616 | Liver | NAFLD | organic cyclic compound catabolic process | 105/1882 | 495/18723 | 7.04e-14 | 5.15e-11 | 105 |
| GO:00442707 | Liver | NAFLD | cellular nitrogen compound catabolic process | 93/1882 | 451/18723 | 1.04e-11 | 4.34e-09 | 93 |
| GO:00467006 | Liver | NAFLD | heterocycle catabolic process | 92/1882 | 445/18723 | 1.16e-11 | 4.52e-09 | 92 |
| GO:00458617 | Liver | NAFLD | negative regulation of proteolysis | 66/1882 | 351/18723 | 4.02e-07 | 2.58e-05 | 66 |
| GO:00072543 | Liver | NAFLD | JNK cascade | 38/1882 | 167/18723 | 1.12e-06 | 5.52e-05 | 38 |
| GO:00514036 | Liver | NAFLD | stress-activated MAPK cascade | 47/1882 | 239/18723 | 5.26e-06 | 1.93e-04 | 47 |
| GO:00310986 | Liver | NAFLD | stress-activated protein kinase signaling cascade | 48/1882 | 247/18723 | 5.89e-06 | 2.07e-04 | 48 |
| Page: 1 2 3 4 5 6 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| AMBP | SNV | Missense_Mutation | c.629A>T | p.Gln210Leu | p.Q210L | P02760 | protein_coding | tolerated(0.38) | benign(0) | TCGA-AR-A1AH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | PD | ||
| AMBP | SNV | Missense_Mutation | c.76N>G | p.Pro26Ala | p.P26A | P02760 | protein_coding | tolerated(0.15) | benign(0.024) | TCGA-D8-A13Y-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| AMBP | SNV | Missense_Mutation | c.477N>C | p.Glu159Asp | p.E159D | P02760 | protein_coding | tolerated(0.8) | benign(0.015) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| AMBP | SNV | Missense_Mutation | rs369822351 | c.610C>T | p.Arg204Trp | p.R204W | P02760 | protein_coding | deleterious(0) | possibly_damaging(0.877) | TCGA-AD-5900-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| AMBP | SNV | Missense_Mutation | c.438N>G | p.Ile146Met | p.I146M | P02760 | protein_coding | tolerated(0.09) | possibly_damaging(0.564) | TCGA-AZ-4681-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| AMBP | SNV | Missense_Mutation | novel | c.973A>G | p.Asn325Asp | p.N325D | P02760 | protein_coding | deleterious(0) | possibly_damaging(0.788) | TCGA-A5-A0GW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| AMBP | SNV | Missense_Mutation | novel | c.828N>T | p.Glu276Asp | p.E276D | P02760 | protein_coding | tolerated(0.15) | benign(0.01) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| AMBP | SNV | Missense_Mutation | c.782A>G | p.Tyr261Cys | p.Y261C | P02760 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| AMBP | SNV | Missense_Mutation | c.205N>A | p.Val69Met | p.V69M | P02760 | protein_coding | deleterious(0.03) | benign(0.357) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| AMBP | SNV | Missense_Mutation | rs748722080 | c.281N>T | p.Thr94Met | p.T94M | P02760 | protein_coding | tolerated(0.28) | benign(0.017) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |